Tadrous M, et al. - In this population-based cohort study, researchers examined patients 66 years and older receiving mirabegron for overactive bladder (OAB) to assess the risk of cardiac arrhythmias and other cardiovascular events. Using health care administrative data from 38,818 patients who started treatment, matching 16,948 patients who received mirabegron to 21,870 patients who were given other OAB drugs. Exposure groups displayed similar 1-year cumulative incidence (adjusted for person-years) of arrhythmia or tachycardia events (3.6% for mirabegron vs 3.8% for other OAB drugs). No association of mirabegron with an increased risk of MI or stroke was observed when compared with other OAB drugs.